La maggior parte delle infezioni gastrointestinali si autolimita e si risolve nell’arco di pochi giorni. Comunque, nei neonati/bambini, nei pazienti immunocompromessi o negli anziani, le infezioni gastrointestinali possono essere potenzialmente gravi.
La diagnosi delle infezioni gastrointestinali è largamente effettuata attraverso test di laboratorio, usati per la coltura o rilievo degli antigeni da campioni di feci. Il Clostridium difficile, un bacillo sporigeno e gram positivo, produce 2 esotossine: la tossina A e la tossina B. Queste tossine sono responsabili nello sviluppo della diarrea e dell’infiammazione presenti nei pazienti infetti. La tossina A è un’enterotossina che può causare un vasto danno a livello delle mucose, ed è un attivatore dei mastociti e dei neutrofili, che scatenano la cascata infiammatoria.
La tossina B è una citotossina che può causare cambi morfologici a livello delle colture cellulari. L’Helicobacter pylori è un batterio spiriforme, che vive nel muco del tratto digestivo umano ed è presente in circa metà della popolazione mondiale. Strettamente associato con l’ulcera peptica e la gastrite cronica attiva, l’H. pylori è il maggior fattore di rischio per lo sviluppo dell’adenocarcinoma gastrico.
La diagnosi di infezione si avvale di metodi non invasivi, come il rilievo dell’antigene dell’H. pylori nei campioni di feci. La ricerca dell’antigene nel campione fecale rappresenta una semplice alternativa all’urea breath test ed è un metodo appropriato per la diagnosi e il follow up dell’infezione.
The LIAISON® Campylobacter assay uses chemiluminescent immunoassay (CLIA) technology for the qualitative determination of Campylobacter antigens in human stool specimens. The test may be used as an aid in the diagnosis of acute bacterial gastroenteritis. The assay must be performed on the LIAISON® Analyzer family.
The DiaSorin LIAISON® Calprotectin Assay is an in vitro diagnostic chemiluminescent immunoassay (CLIA) intended for the quantitative measurement, in human stool, of fecal calprotectin, a neutrophilic protein that is a marker of mucosal inflammation. The LIAISON® Calprotectin Assay can be used as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, and as an aid in differentiation of IBD from irritable bowel syndrome (IBS). Test results are to be used in conjunction with information obtained from the patients’ clinical evaluation and other diagnostic procedures.
The test has to be performed on the LIAISON® Analyzer Family.
The DiaSorin LIAISON® C. difficile GDH Assay is a chemiluminescent immunoassay (CLIA) intended for use as a screening assay to detect Clostridium difficile antigen, glutamate dehydrogenase, in human feces from persons suspected of having C. difficile disease
Pancreatic insufficiency is the inability of the exocrine pancreas to produce and/or transport enough digestive enzymes to break down food in the intestine and facilitate absorption of nutrients. It typically occurs as a result of progressive pancreatic damage that may be caused by recurrent acute pancreatitis or by chronic pancreatitis due to a variety of conditions.
Failure in any of the digestive metabolic steps may be the result in pancreatic exocrine insufficiency (PEI). Current methods for evaluating digestion, such as fecal fat quantification and the 13C-mixed triglycerides test, are the most used and known tests but are complicated and sometimes need long execution times. With the introduction of the new automated chemiluminescence assay LIAISON® Elastase-1, testing is easier and quickly done avoiding complicated procedures and execution steps.
The DiaSorin LIAISON® C. difficile Toxins A&B Assay is a chemiluminescent immunoassay (CLIA) intended for the qualitative determination of Clostridium difficile toxins A and B in human feces on the LIAISON® Analyzer. Assay results should be used in conjunction with other clinical and laboratory data to assist the clinician in making individual patient management decisions.
The DiaSorin LIAISON® Meridian H. pylori SA is a chemiluminescent immunoassay (CLIA) intended for the qualitative determination of H. pylori stool antigen in human feces on the LIAISON® Analyzer. The test is an aid in the diagnosis of H. pylori infection and to monitor response during and post-therapy in patients. Assay results should be used in conjunction with other clinical and laboratory data to assist the clinician in making individual patient management decisions.
The DiaSorin LIAISON® Rotavirus assay is an in vitro diagnostic chemiluminescent immunoassay (CLIA) intended for the qualitative determination of rotavirus antigen in human stool specimens. This test is used primarily as an aid for the diagnosis of acute viral gastroenteritis. Test results are to be used in conjunction with information obtained from the patients’ clinical evaluation and other diagnostic procedures. The assay must be performed on the LIAISON® Analyzer.
The DiaSorin LIAISON® Adenovirus assay is an in vitro diagnostic chemiluminescent immunoassay (CLIA) intended for the qualitative determination of adenovirus antigen in human stool specimens. This test is used primarily as an aid for the diagnosis of acute viral gastroenteritis. Test results are to be used in conjunction with information obtained from the patients’ clinical evaluation and other diagnostic procedures. The assay must be performed on the LIAISON® Analyzer Family*.
The DiaSorin LIAISON® EHEC Toxins assay is an in vitro diagnostic chemiluminescent immunoassay (CLIA) intended for the qualitative detection of Shiga toxins 1 and 2 in stool specimens, broth cultures, and from individual colonies or colony sweeps of agar plates. The LIAISON® EHEC Toxins assay is intended for use as an aid in the diagnosis of Enterohemorrhagic E. coli (EHEC) infections. Test results are to be used in conjunction with information obtained from the patients’ clinical evaluation and other diagnostic procedures. The assay must be performed on the LIAISON® Analyzer Family.
